Immutep Limited American Depositary Shares - IMMP STOCK NEWS

Immutep, a biotechnology company focusing on LAG-3 immunotherapy, will present final Overall Survival (OS) data from its Phase IIb AIPAC trial for eftilagimod alpha (efti) in metastatic breast cancer at the SITC Annual Meeting 2021 from November 10-14. This late breaker poster presentation follows interim data showcased at the San Antonio Breast Cancer Symposium in December 2020, demonstrating a median survival benefit of +2.7 months for the efti group. The AIPAC trial enrolled 227 patients and aims to enhance immune responses against tumors.

Immutep Limited (NASDAQ: IMMP) has successfully completed patient recruitment for Stage 2 of Part B in its Phase II TACTI-002 clinical trial, focusing on PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC). A total of 154 out of an expected 183 patients are now enrolled, with ongoing recruitment for the expansion stage of Part A. Preliminary data presented indicated a positive risk-benefit ratio in this challenging patient population. Further results are anticipated by early 2022.

Immutep Limited (NASDAQ: IMMP) announced that its Chinese partner, EOC Pharma, plans to expand its clinical trial pipeline for eftilagimod alpha (efti) in China. EOC is set to initiate a new clinical trial combining efti with an anti-PD-1 therapy in the first half of 2022. This follows promising data from ASCO 2021 and EOC's earlier Phase II trial in metastatic breast cancer, slated for the second half of 2021. EOC, responsible for efti's development in Greater China, has received positive feedback for its manufacturing processes from China's regulatory authorities.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced the grant of patent no. ZL201580013695.X by the Chinese Patent Office for LAG525, an antibody molecule aimed at treating cancer and infectious diseases. This patent follows prior grants in Australia, the U.S., Europe, and Japan. LAG525, a humanized form of IMP701, is currently being evaluated in clinical trials in collaboration with Novartis AG. The patent, set to expire on March 13, 2035, is co-owned by Novartis and Immutep S.A.S.

Immutep has announced that the first patient has been enrolled and dosed in the INSIGHT-003 trial, evaluating a triple combination therapy for metastatic non-small cell lung carcinoma. This innovative approach combines Immutep’s lead product candidate, eftilagimod alpha (efti), with standard chemotherapy and anti-PD-1 therapy. The trial aims to recruit up to 20 patients, with initial results expected in 2022, marking a significant milestone in cancer treatment research.

Immutep Limited has entered late-stage development in the LAG-3 immunotherapy space, focusing on its lead product, eftilagimod alpha (efti). Recent data presented at ASCO highlights its efficacy in treating non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). Immutep is collaborating with Merck KGaA for a new trial evaluating efti with bintrafusp alpha. The company plans to initiate a Phase III study in metastatic breast cancer, while cash reserves have increased to $60.59 million as of June 30, 2021.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has received FDA and IRB approval to launch the TACTI-003 trial, assessing the efficacy of its lead product candidate, eftilagimod alpha, in combination with KEYTRUDA in first-line treatment for Head and Neck Squamous Cell Carcinoma (HNSCC). Recruitment for the trial, which will include around 154 patients, is set to begin this quarter, with locations across Australia, Europe, and the U.S. Immutep aims to evaluate overall response rates and other efficacy metrics in this pivotal study.

Immutep announced a successful A$60 million private placement of new ordinary shares to professional and institutional investors. The first tranche will be completed without shareholder approval, while the second tranche awaits approval. Funds will support the expansion of clinical programs and manufacturing processes for eftilagimod alpha. New Shares will be issued at A$0.52 each, reflecting a 12.9% discount. Settlement dates are set for late June and July 2021. Additionally, a share purchase plan targeting A$5 million will be offered to eligible shareholders.

Immutep Limited has announced the initiation of a new Phase I clinical trial, INSIGHT-003, aimed at evaluating the combination of its lead product candidate, eftilagimod alpha (efti), with chemotherapy and anti-PD-1 therapy in patients with various solid tumors. The trial will recruit up to 20 patients, with the expected first patient enrollment in Q3 2021 and interim results anticipated in 2022. All regulatory approvals are in place for the trial, marking a significant step in enhancing treatment options for cancer patients.